Filter by: patients
Home > Community Treatment Reports and Side Effects > Calcitonin Treatment Report
What is Calcitonin?

Calcitonin is used in the treatment of Paget's disease of bone; adjunctive therapy for hypercalcemia and treatment of osteoporosis postmenopausal women. It is available in nasal spray and injectable formulation.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Osteoporosis 3 1 Efficacy_major
Other 2 1 Efficacy_cant_tell
Support bone health 1 0
Pain 1 0
Kidney Transplant 1 0
Increase effect of another treatment 1 0

See all 8 patients currently taking Calcitonin

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 2

Reported Dosages

  1 mg daily 200 intl units daily
  1 Number of Patients: 1 7 Number of Patients: 7  

Reported Stop Reasons

Why Patients Stopped Taking Calcitonin (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 50%
Other 1   Other: 50%

See all 2 patients who’ve stopped taking Calcitonin

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Calcitonin

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Calcitonin

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Calcitonin

Always
 2 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Calcitonin

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 2 100%

Cost

Paid out of pocket

Cost of Calcitonin

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 11, 2012.